Health Alert:

Coronavirus Information: Vaccinations | Testing | Safety Policies & Visitor Guidelines | Appointments & Scheduling | FAQs

Covid Calls

Vaccine Scheduling Update: We’re experiencing very high call volumes from people interested in getting the COVID-19 vaccine. Currently, our vaccine supply is very small, and we are unable to accept phone calls to schedule vaccine appointments. Please check back here for updates.

Hospital of the University of Pennsylvania Pharmacy Residency

Former Residents

Danielle Cenin, PharmD

  • Current Position: Clinical Pharmacy Specialist, Leukemia and Bone Marrow Transplant Cleveland Clinic
  • 2019-2020: PGY2 Oncology – Hospital of the University of Pennsylvania
  • 2018-2019: PGYI Hospital of the University of Pennsylvania

Sheriff Gbadamosi, PharmD

  • Current Position: Clinical Pharmacy Specialist, Surgical Critical Care at Temple University Hospital
  • 2019-2020: PGY2 Critical Care – Hospital of the University of Pennsylvania

Christopher Goncalo, PharmD

  • Current Position: Pharmacy Manager, Medication-Use Systems Automation at the Hospital of the University of Pennsylvania
  • 2019-2020: PGY2 Health System Pharmacy Administration Leadership – Hospital of the University of Pennsylvania

Kerry Lenzi, PharmD

  • Current Position: Clinical Pharmacy Specialist, Neurology at the Hospital of the University of Pennsylvania
  • 2019-2020: PGY2 Ambulatory Care– Hospital of the University of Pennsylvania
  • 2018-2019: PGYI Hospital of the University of Pennsylvania

Katherine Mersinger, PharmD

  • Current Position: Infectious Disease Clinical Pharmacy Specialist, University of Pittsburgh Medical Center
  • 2019-2020: PGY2 Infectious Diseases Hospital of the University of Pennsylvania
  • 2018-2019: PGYI Hospital of the University of Pennsylvania

Maxwell Norris, PharmD

  • Current Position: Clinical Pharmacy Specialist, Cardiothoracic Transplant at the Hospital of the University of Pennsylvania
  • 2019-2020: PGY2 Solid Organ Transplant Hospital of the University of Pennsylvania
  • 2018-2019: PGYI Hospital of the University of Pennsylvania

Research, Awards, and Publications



Preceptor Awards, Appointments, and Grants
Vasilios Athans, PharmD, BCPS, BCIDP
Infectious Diseases
  • Preceptor of the Year 2019 – 2020, Hospital of the University of Pennsylvania
Apple L. Apple, PharmD, MS
Chief Pharmacy Operator
  • First recipient of the prestigious Fred M. Eckel Pharmacy Leadership Award from the University of North Carolina Hospitals and Clinics
Meghan Caylor, PharmD, BCPS, BCCCP 
Neurocritical Care
  • Society of Critical Care Medicine (SCCM) Presidential Citation Award – 2017, 2018, 2019
  • Neurocritical Care Society 15th Annual Meeting Travel Grant Award – 2017
Jennifer Trofe-Clark, PharmD, FAST, FCCP, BCPS
Clinical Transplant Pharmacist
  • American Society of Transplantation Clinician of Distinction Award 2018
  • Recipient of the American Society of Transplantation/Transplant Immunology Research Network/Wood MacMillan Charitable Fund Allied Health Science Research Grant for research entitled: Assessments of Literacy, Cognitive Function and Medication Knowledge in Renal Transplant Recipients in the Ambulatory Care Setting 2017
  • Elected Fellow of the American Society of Transplantation (FAST) 2015
Jaimie Gray, PharmD, BCCCP, FCCM
PGY2 Residency Program Director Critical Care
  • Fellow of Critical Care Medicine (FCCM) American College of Critical Care Medicine 2019

  • Quality and Patient Safety Award at the Hospital of the University of Pennsylvania – Implementation of PAD guidelines in the Rhoads 5 SICU to decrease variations in care 2014 – 2015
Justin Harris, PharmD, BCPS, BCCP
Cardiology
  • Associate of American College of Cardiology 2019
  • Preceptor of the Year 2018 – 2019, Hospital of the University of Pennsylvania
Donna Capozzi, PharmD, BCOP
Associate Director Pharmacy
  • 1st Place Title, Adherence – Appropriate Prescribing of Antiemetic’s with Oral Oncolytic Therapy: A Single Center Experience – National Association of Specialty Pharmacy Annual Meeting, September 2019
Mitchell Hughes, PharmD, BCPS, BCOP
Ambulatory – Hematology/Oncology
  • Research Grant Award – UPCC 19419: A pharmacogenomic evaluation of ibrutinib for treatment of B-cell malignancies. HOPA and Acerta Pharma, a member of the AstraZeneca group, February 2019–present
Tanya Uristky, PharmD
Pain and Palliative Care
  • PSHP Joe E. Smith Award 2020 – Recipient for excellence in practice, professional and community service
  • Preceptor of the Year 2016 – 2017, Hospital of the University of Pennsylvania
  • PAIN Week’s Pain and Palliative Care Practitioner of the Year – September 2015
  • United State Licensing Examination Test Material Development Committee Appointment 2021 – 2023
  • ASHP Pain Certificate Reviewer and Consultant, Final Exam Content Developer, February 2020 – Present
  • TRC Hospital Pharmacist’s Letter Opioid Stewardship Training Modules Lead Grant Writer/SME, February 2020 – Present
  • Hospice and Palliative Care EPA Development Workgroup Faculty Appointment, Cambia Health Foundation Project, March 2020 – Present
  • Society of Pain and Palliative Care Pharmacists Chair – Opioid Stewardship Task Force, August 2019 – Present
  • American Society of Health Systems Pharmacy Pain and Palliative Care Special Advisory Group, Chair 2018 – 2019; Vice-Chair 2017-2018
  • Anesthesia Pain Fellowship, July 2020 – Present
  • Penn Medicine’s Center for Addictions and Medication Policy, November 2019 – Present
  • Penn Medicine Palliative Care Fellowship, July 2016 – Present
Preceptor Publications (peer reviewed, non-peer reviewed, and books)
Vasilios Athans, PharmD, BCPS, BCIDP
Infectious Diseases
  • Implementation and effect of weekend pharmacy-driven antimicrobial stewardship services at a large academic medical center. J Pharm Pract 2020.
  • Alternative pneumocystis prophylaxis in solid organ transplant recipients at two large transplant centers. Transpl Infect Dis 2020.
  • Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. Open Forum Infect Dis 2020.
  • Itraconazole vs.posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: a retrospective study. Int J Antimicrob Agents 2020.
  • Penicillin allergy testing as an antibiotic stewardship intervention reduces alternative antibiotic exposures in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2020.
  • Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy. J Clin Virol 2019.
  • Clinical experience with the use of novel cephalosporin/beta-lactamase inhibitor combinations among solid organ transplant recipients. Transpl Infect Dis 2019.
  • Clinical and microbiological outcomes in obese patients receiving colistin for carbapenem-resistant gram-negative bloodstream infection. Antimicrob Agents Chemother 2019.
  • Evaluation of an electronic antimicrobial time-out on antimicrobial utilization at a large health system. Infect Control Hosp Epidemiol 2019.
  • Real-word use – isavuconazole at a large academic medical center. Mycoses 2019.
  • Impact of asymptomatic bacteriuria incidence and management post-kidney transplantation. Clinical Transplantation 2019.
  • Implementation of a stewardship initiative on respiratory viral PCR-based antibiotic de-escalation. Pharmacotherapy 2019.
  • Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother 2018.
  • A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in solid organ transplant recipients. Transpl Infect Dis 2018.
  • Vaccines. In: Ray SD, ed. Side Effects of Drugs Annual, Volume 41. Amsterdam, Netherlands: Elsevier (2018).
  • Vaccines. In: Ray SD, ed. Side Effects of Drugs Annual, Volume 41. Amsterdam, Netherlands: Elsevier (2019).
  • Antimicrobial Stewardship in Critical Care. In: Wood C, ed. Critical Care Self-Assessment Program. Book 1: Infection Critical Care. Lenexa, KS: American College of Clinical Pharmacy (2019).
  • BCIDP Quarterly Journal Club Series. A randomized trial of hydroxychloroquine for the treatment of COVID-19. Society of Infectious Diseases Pharmacists (2020).
Meghan Caylor, PharmD, BCPS, BCCCP 
Neurocritical Care
  • Caylor MM, Balu R. “Special ICU Populations: Opioid Use in Neurocritical Care.” In: Opioid Use in the ICU: A Practical Guide. Jose L. Pascual and Timothy G. Gaulton (eds.). Springer Nature. [in press]
  • Caylor MM, Sherma A. “Paroxysmal Sympathetic Hyperactivity.” In: Decision Making in Neurology. Brett Cucchiara and Raymond Price (eds.). Elsevier. [in press]
  • Panos NG, Cook AM, John S et al. Factor Xa Inhibitor-Related Intracranial Hemorrhage (FiX-ICH): Results from a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. The Neurocritical Care Society Pharmacy Study Group. Circulation. 2020;141(21):1681-9.
  • Hammond DA, Holt TR, Harris SA, Caylor MM, Kopp BJ, Hamblin S. Perceptions of critical care pharmacists participating in a formal mentor-mentee program. Am J Health-Syst Pharm. 2018;75(21):1691-93.
  • Levine JM, Caylor MM, Kumar MA, Morrison C, Moyer M. “Traumatic Brain Injury.” Neurocritical Care ON CALL. The Neurocritical Care Society, 6, August 2018.
  • Sullivan K, Caylor MM, Lin FC, Campbell-Bright S. Comparison of amphotericin B bladder irrigations versus fluconazole for the treatment of candiduria in intensive care unit patients. J Pharm Pract. 2017;30(3):347-352.
  • Stollings J, Caylor MM. Post-intensive care syndrome and the role of a follow-up clinic. Am J Health-Syst Pharm. 2015;72:1315-1323.
Tamara Claridge, PharmD, BCPS
Solid Organ Transplant
  • Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, Shullo M, Schweiger M, Weill D, Stuckey L, Ivulich S, Scheel J, Peters L, Colvin M, Dawson K, Girgis R, Weeks P, Tse T, Russell S, Flattery M, Jennings D, Kittleson M, Miller T, Khuu T, Claridge T, Uber P, Ford K, Ensor CR, Simpson K, Dipchand A, Page RL 2nd. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. J Heart Lung Transplant. 2020 Jul 10:S1053-2498(20)31646-6.
  • Lerman DT, Hamilton KW, Byrne D, Lee DF, Zeitler K, Claridge T, Gray J, Minamoto GY. The impact of infection among left ventricular assist device recipients on post-transplantation outcomes: a retrospective review. Transpl Infect Dis 2018;20(6)
Jennifer Trofe-Clark, PharmD, FAST, FCCP, BCPS
Clinical Transplant Pharmacist
  • Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark, J. Increased risk of breakthrough infection among cytomegalovirus donor positive/recipient negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transplant Infectious Disease 2015; 17: 163-73.
  • Varga, A, Johnson D, Sawinski DL, Lim MA, Bloom RD, Abt PL, Goral S, Bleicher M, Levine MH, Naji A, Nazarian S, Porrett P, Trofe-Clark J. Safety and feasibility of outpatient rabbit antithymocyte globulin induction therapy administration in kidney transplant recipients. Pharmacotherapy 2018; 38:620-27.
  • Hamel S, Kuo K, Sawinski D, Johnson D, Bloom RD, Bleicher M, Goral S, Lim AM, Trofe-Clark J. Single center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clinical Transplantation 2019 Mar 19:e13541.
  • Persun N, Johnson D, Leonberg-Yoo A, Bahrainwala J, Reese PP, Steiner B, Witmer B, Rashid J, Naji A, Trofe-Clark J. Dietary supplement use in live kidney donors and recipients. Transplant Research and Risk Management 2020; 2020: 12: 9-14.
  • Leonberg-Yoo A, Johnson D, Persun N, Bahrainwala J, Reese PP, Naji A, Trofe-Clark J. Critical review of dietary supplements: Precautions in a living kidney donor population. American Journal of Kidney Diseases 2020 Jul 10; S0272-6386(20)30794-0. doi: 10.1053/j.ajkd.2020.03.030.Online ahead of print.
  • Sawinski D, Forde KA, Trofe-Clark J., Patel P, Olivera B, Goral S, Bloom RD. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. Journal of the American Society of Nephrology 2015 26:966-75.
  • Taber DJ, Pilch NA, Trofe-Clark J, Kaiser TE. A national survey assessing the current workforce of transplant pharmacists across accredited U.S. solid organ transplant programs. American Journal of Transplantation 2015; 15:2683-90.
  • Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. American Journal of Transplantation 2016; 16: 1588–95.
  • Sawinski D, Trofe-Clark J, Leas B, Uhl S, Tuteja S, Kaczmarek JL, French B, Umscheid CA. Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-analysis. American Journal of Transplantation 2016; 16:2117-38.
  • Reese PP, Bloom RD, Trofe-Clark J, Mussell, A, Leidy D, Levsky S, Zhu J, Lin Y, Wang W, Troxel A, Feldmen HI, Volpp K. Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients: a randomized trial. American Journal of Kidney Diseases. 2017;69:400-9. (note includes mention of pharmacy residents in acknowledgements)
  • Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold J, Reese PP. Comparing outcomes between antibody induction therapies in kidney transplantation. Journal of the American Society of Nephrology. 2017; 28:2188-2200.
  • Higdon LE, Trofe-Clark J, Liu S, Margulies KB, Sahoo MK, Blumberg E, Pinsky BA, Maltzman JS. Cytomegalovirus responsive CD8+ T cells expand after solid organ transplantation in the absence of CMV disease. American Journal of Transplantation. 2017; 17:2045-54.
  • Lim MA, Palmer M, Trofe-Clark J, Bloom RD, Jackson A, Philogene MC, Kamoun M. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. Human Immunology 2017; 78:350-56.
  • Vallabhajosyula P, Korutla L, Habertheuer A, Yu M, Rostami S, Yuan CX, Reddy S, Liu C, Korutla V, Koeberlein B, Trofe-Clark J, Rickels MR, Naji A. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. Journal of Clinical Investigation. 2017; 127:1375-91.
  • Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, Bloom RD, Nazarian SM, Sawinski D, Porrett P, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Farooqi M, Gentile C, Smith J, Reese PP.Trial of Transplantation of HCV-infected kidneys into uninfected recipients. [Correspondence] New Engl J Med 2017; 376:2394-95.
  • Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate release tacrolimus versus extended release tacrolimus in African American kidney transplant recipients. American Journal of Kidney Diseases. 2018; 71:315-26.
  • Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, Levine M, Porrett P, Sawinski D, Nazarian SM, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Gentile C, Smith J, Niknam BA, Bleicher M, Reddy KR, Goldberg DS. Twelve-month outcomes after transplant of Hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Annals of Internal Medicine. 2018; 169:273-81.
  • Shah A, Kumar V, Palmer MD, Trofe-Clark J, Laskin B, Sawinski D, Hogan JJ. Native kidney BK virus nephropathy, a systematic review. Transplant Infectious Disease 2019 Mar 25:e13083.
  • Cohen JB, Lim MA, Tewksbury CM, Torres-Landa S, Trofe-Clark J, Abt PL, Williams NN, Dumon KR, Goral S. Bariatric surgery before and after kidney transplantation: long-term weight loss and allograft outcomes. Surgery for Obesity and Related Diseases 2019; 15: 935-41.
  • Morrison AH, Gupta M, Lloyd K, Trofe-Clark J, Lim MA, Limonte C, Levine MH, Sawinski D, Kamoun M, Porrett PM. Class and kinetics of weakly reactive pretransplant donor-specific HLA antibodies predict rejection in kidney transplant recipients. Transplantation Direct. 2019;5:e478. doi: 10.1097/TXD.0000000000000926
  • Ramadan O, Naji A, Levine MH, Porrett PM, Dunn TB, Nazarian SM, Weinrieb RM, Kaminski M, Johnson D, Trofe-Clark J, Lorincz I, Blumberg EA, Weikert BC, Bleicher M, Abt PL. Kidney transplantation and donation in the transgender population: a single-institution case series. American Journal of Transplantation; 2020 Apr 30. doi: 10.1111/ajt.15963. [Epub ahead of print]
  • Alloway RR, Trofe-Clark J, Brennan DC, Kerr J, Cohen EA, Meier-Kriesche U, Stevens DR, Moten MA, Momper JD. Single-dose chronopharmacokinetics and food-effect of LCP-Tacrolimus in health volunteers. Therapeutic Drug Monitoring 2020 May 19. doi: 10.1097/FTD.0000000000000773. Online ahead of print.PMID: 32453306
  • Pilch NM, Park JM, Lichvar A, Kane C, Bowman L, Melaragno JI, Sobhanian M, Perez C, Trofe-Clark J, Fleming JN. Observations from a systematic review of pharmacist-led research in solid organ transplantation: an opinion paper of the ACCP Immunology/Transplantation Practice and Research Network. Accepted to Journal of the American College of Clinical Pharmacy 2020 July. doi: 10.1002/jac5.1294. (Online ahead of print)
  • Trofe-Clark J, Kaiser TK, Pilch N, Taber D. Value of solid organ transplant-trained pharmacists in transplant infectious diseases. Current Infectious Disease Reports 2015; 17: 19. doi:10.1007/s11908-015-0475-8.
  • Sawinski D, Trofe-Clark J. BKV viremia and development of de novo DSA in renal transplant recipients. Clinical Transplantation 2015; 31: 249-56.
  • Trofe-Clark J, Sawinski D. BK and other polyomaviruses in kidney transplantation. Seminars in Nephrology 2016;36 :372-85.
  • Maldonado A, Johnson D, Trofe-Clark, J. Barriers to vaccination in renal transplant. Transplant Infectious Disease. 2017; 19: e12749.
  • Sawinski D, Trofe-Clark J. BK virus nephropathy. Clinical Journal of the American Society of Nephrology 2018; 13:1893-96.
Jaimie Gray, PharmD, BCCCP, FCCM
PGY2 Residency Program Director Critical Care
  • Lerman D, Hamilton K, Byrne D, Lee D, Zeitler K, Claridge T, Gray J, Minamoto G. The Impact of Infection Among Left Ventricular Assist Device Recipients on Post-Transplantation Outcomes: A Retrospective Review. Transpl Infect Dis. 2018;e12995. (2018)
  • Jablonski J, Gray J, Miano T, Redline G, Teufel H, Collins T, Pasqual-Lopez J, Sylvia M, Martin N. Pain, Agitation, and Delirium guidelines – Interprofessional perspectives to translate the evidence. Dimens Crit Care Nurs. 2017;36(3):164-173. (2017)
  • Gray J, Teufel HM. Endocrine Emergencies in the ICU. In: Murphy JE, Lee MW, eds. Pharmacotherapy Self-Assessment Program 2020 Book 1. Critical and Urgent Care. Lenexa, KS: American College of Clinical Pharmacy, January 2020.
  • Teufel HM, Gray J. Chronic Pancreatitis. In: Schwinghammer TL, Koehler JM. Pharmacotherapy Casebook: A Patient-Focused Approach. 11th ed. New York: McGraw-Hill, 2020.
Justin Harris, PharmD, BCPS, BCCP
Cardiology
  • Harris JR, Hatch R, Vallabhajosyula P, Patel N. Morning vs Evening Administration of Warfarin Following Cardiac Surgery. Journal of Pharmacy Technology 2020. [Accepted - in progress]
  • Barlow A, Barlow B, Reinaker T, Harris JR. Potential role of direct oral anticoagulants in the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2019 June; 39(8):837-53.
  • Harris JR, Teuteberg J, Shullo M. Optimal low-density lipoprotein concentration for cardiac allograft vasculopathy prevention. Clin Transplant. 2018 May;32(5).
  • Harris JR, Hale G, Dasari TW, Schwier NC. Pharmacotherapy of Vasospastic Angina. Journal of Cardiovascular Pharmacology and Therapeutics. 2016 Sep;21(5):439-51.
Mitchell Hughes, PharmD, BCPS, BCOP
Ambulatory – Hematology/Oncology
  • Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Fry NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. Leukemia & Lymphoma. 2020;published online 01 Jun 2020.
  • Namoglu EC, Hughes ME, Plastaras JP, Landsburg DJ, Maity A, Nasta SD. Management and outcomes of sinus histiocytosis with massive lymphoadenopathy (Rosai Dorfman disease). Leukemia & Lymphoma. 2020;61(4):905-911.
  • Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD. Treatment of relapsed/refractory non Hodgkin lymphoma patients with venetoclax therapy: A single-center evaluation of off-label use. Clinical Lymphoma, Myeloma and Leukemia. 2019;19(12):791-8.
  • Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks K, Guo L, Winter AM, Hill B, Ondrejka SL, His ED, Nasta SD, Svoboda J, Schuster SJ, Bogusz A. Outcomes of patients with relapsed/refractory double expressor B cell lymphoma treated with ibrutinib monotherapy. Blood Adv. 2019;3:132-135.
  • Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, Stadtmauer EA, Porter DL. Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68(12):2003-2009.
  • Leung TV, Hughes ME, Cambareri CC, Rubin DR, Sandy EA. Systemic treatments for lung cancer patients receiving hemodialysis. J Adv Pract Oncol. 2018;9(6):614-629.
  • Hughes ME, Gill J. Primer on chronic lymphocytic leukemia: Part II. JNP. 2018;14(4):309-315.
  • Gill J, Hughes ME. Primer on chronic lymphocytic leukemia: Part I. JNP. 2018;14(4):302-308.
  • Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes ME, Nabhan C, Ali N, Schuster S, Carver J. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biology & Therapy. 2018;19(1):1-2.
Maxwell Norris, PharmD
Cardiothoracic Transplant
  • Bohan, G., Trofe-Clark, J., Fallah, T., Norris, M., Bloom, R. D., Sawinski, D., Malat, G. Does historical use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers therapy slow allograft function recovery following successful kidney transplantation. American Transplant Congress. Philadelphia, PA. May 2020
  • Puerzer, P., McIntosh, T., Sammons, C., Casciello, N., Fallah, T., Norris, M., Sumit, M., DuBois, J., Iltis, A., Sawinski, D. Patient attitudes regarding contraception and pregnancy after transplantation. American Transplant Congress. Philadelphia, PA. May 2020.
  • Norris, M., Trofe-Clark, J., Casciello, N., Cardillo, S., Sawinski, D., Bloom, R. D., Malat, G. Characterization of use and safety of non-insulin agents for management of post-transplant diabetes mellitus in the kidney transplant population. Vizient Consortium Pharmacy Network Meeting. Las Vegas, NV. Dec 2019.
  • Persun, N., Norris, M., Casciello, N., Johnson, D., Trofe-Clark, J., Sammons, C. Renal function outcomes at 6 and 12 months in orthotopic liver transplant recipients utilizing a calcineurin inhibitor minimization strategy: a retrospective, single-center review. ASHP Midyear Clinical Meeting and Exhibition. Anaheim, CA. Dec 2018.
Tanya Uristky, PharmD
Pain and Palliative Care
  • Paniagua M, Uritsky TJ. Symptom Management. In Clinicians Pocket Reference, In Print.
  • Dingfield, LE. Flores EJ, Radcliff JA, Stamm R, Uritsky TJ. Adapting a comfort care orderset in a large health system during the COVID-19 pandemic. J Palliat Med 2020; doi: 10.1089/jpm.2020.0277.
  • Foxwell A, Uritsky TJ, Meghani, S. Opioids and cancer pain management in the United States: Public policy and legal challenges. Seminars in Oncology Nursing, 2019; 1-5.
  • Riordan PA, Biscoe J, Uritsky TJ, Jones CA, Webb JA. Top ten tips palliative care providers should know about psychopharmacology. J Palliat Med, 2019; 22(5):572-579. DOI: 10.1089/jpm.2019.0106.
  • Uritsky TJ. Methylnaltrexone: Peripherally-Acting: µ-Opioid Receptor Antagonist. J Adv Pract Oncol. 2019;10(1):62-67.
  • Uritsky TJ, Atayee RS, Herndon CM, Lockman KS, McPherson ML, Jones CA. Top ten tips palliative care pharmacists want the palliative care team to know when caring for patients. J Palliat Med, 2018;21(7):1017-1023. DOI: 10.1089/jpm.2018.0187.
  • Foxwell A, Uritsky TJ. Hydromorphone Conversions: A Millennial Problem, J Pain Symp Manage, Published Online, May 15 2018.
  • Uritsky TJ. “Pharmacist’s Perspective on Moral Distress in Palliative Care: A Narrative.” Moral Distress: Disciplinary Perspective, in Moral Distress in the Health Professions. Ed. CM Ulrich and Grady C. Springer International Publishing, 2018.
  • Wdowiarz K, Uritsky TJ. The Pharmacist’s Role in Palliative Care in: Coyne PJ, et al. Conversations in Palliative Care, 4th Ed. Hospice and Palliative Nurses Association; 2017: 253-261.
  • Leah Sera & Tanya Uritsky. Pharmacokinetic and pharmacodynamic changes in older adults and implications for palliative care. Progress in Palliative Care, July 2016. DOI: 10.1080/09699260.2016.1192319
  • Mendlik M, Uritsky TJ. Treatment of neuropathic pain. Curr Treat Options Neurol [Internet] December 2015;17:50: 1-15. DOI: 10.1007/s11940-015-0381-2
  • Kral LA, Jackson K, Uritsky TJ. A practical guide to tapering opioids. Mental Health Clin [Internet] 2015; 5(3):102-108. DOI: http://dx.doi.org/10.9740/mhc.2015.05.102
  • Uritsky TJ. A Wrinkle in the Plan: Metabolic changes and pain management in the older adult. PainWeek Journal, 2018 (Q3); v2: 22-29
  • Uritsky TJ. Clinical Pearls: Ketamine in Palliative Care. AAHPM Quarterly. Spring 2018;19(1): 8-9.
  • Uritsky, TJ. A new approach to managing cancer-related pain. Coping With Cancer Magazine (in-print and on-line), January/February 2017.
Preceptor Abstracts
Vasilios Athans, PharmD, BCPS, BCIDP
Infectious Diseases
  • Predictors of negative clinical outcomes among patients treated with meropenem-vaborbactam for serious gram-negative bacterial infections: impact of delayed appropriate antibiotic selection (Poster #1575). IDWeek Conference. Virtual Meeting. October 2020.
  • Effectiveness of a venous catheter stewardship intervention targeting parenteral antimicrobial therapy at hospital discharge (Poster #54). IDWeek Conference. Virtual Meeting. October 2020.
  • Comparison of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteremia with a deep-seated source (Poster #275). IDWeek Conference. Virtual Meeting. October 2020.
  • Impact of weekend infectious diseases and antimicrobial stewardship pharmacy services (Poster #1050). ID Week Conference. Washington, D.C. October 2019.
  • Applying antimicrobial consumption metrics to characterize inpatient stewardship opportunities (Poster #2098). IDWeek Conference. Washington, D.C. October 2019.
  • Assessment of guideline-concordant antimicrobial prescribing in urgent care centers (Oral Abstract #1958). IDWeek Conference. Washington, D.C. October 2019.
  • Impact of levofloxacin MIC on outcomes with levofloxacin step-down therapy in Enterobacteriaceae bloodstream infections (Poster #124). IDWeek Conference. Washington, D.C. October 2019.
  • Characterization of antimicrobial superutilizers in an inpatient setting (Poster #1012). IDWeek Conference. Washington, D.C. October 2019.
  • Therapeutic drug monitoring of azole antifungals at an academic medical center: opportunities and lessons learned. (Poster #1810). IDWeek Conference. San Francisco, California. October 2018.
  • Evaluation of an antimicrobial time-out on antimicrobial utilization at a large health system. (Poster #233). IDWeek Conference. San Francisco, California. October 2018.
  • Outcomes of patients with vancomycin-resistant Enterococcus bloodstream infections (BSIs) treated with daptomycin. (Poster #2441). IDWeek Conference. San Francisco, California. October 2018.
  • Urinary tract infections (UTIs) in the first year post-renal transplant: risks and opportunities. (Poster #1508). IDWeek Conference. San Francisco, California. October 2018.
  • Incidence of daptomycin toxicity among patients with vancomycin-resistant Enterococcus bloodstream infections. (Poster #2444). IDWeek Conference. San Francisco, California. October 2018.
Meghan Caylor, PharmD, BCPS, BCCCP 
Neurocritical Care
  • Albaz G, Caylor MM, Sammons C, Bellamy C. Use of midodrine for vasopressor transition in patients with cirrhosis. Poster presentation, Eastern States Conference for Pharmacy Residents and Preceptors, Hershey, PA. (June 2019)
  • Nguyen J, Caylor MM. Effect of therapeutic plasma exchange on antiepileptic drug levels in a patient with seizures. Case report (abstract #846), Research Snapshot presented during SCCM’s 2019 Critical Care Congress, San Diego, CA. (Feb 2019)
Jaimie Gray, PharmD, BCCCP, FCCM
PGY2 Residency Program Director Critical Care
  • Zichichi A, Johnson M, Domenico C, Zeitler K, Miano T, Anesi J, Rame E, Gray J. Impact of Surgical Antibiotic Prophylaxis on Ventricular Assist Device Infections. Crit Care Med. 2018:46(12S): 551.
  • Gray J, Weiner J, Saw S, Redline G, Martinez M, Hamilton K, Gutsche J, Blumberg E, Horak J. Incidence of sternal wound infection following delayed sternal closure – a pilot study. Crit Care Med. 2017:45(12S): 607.
Jennifer Trofe-Clark, PharmD, FAST, FCCP, BCPS Clinical Transplant Pharmacist
  • Trofe-Clark J, Gbemudu W, Hamel S, Shults J, Neubauer R, Ryan S, Kaminski M, Sawinski D, Goral S, Bleicher M, Lim MA, Bloom RD, Reese PP. Cognitive function and health literacy assessment outcomes in the first months after renal transplant in a diverse single center population. Accepted as poster to the American Transplant Congress Meeting, Seattle, WA, June 2018.
  • Hamel S, Kuo V, Johnson D, Bloom RD, Sawinski D, Trofe-Clark J. Use of granulocyte colony-stimulating factor for leukopenia post-renal transplant. Accepted as poster to the American Transplant Congress Meeting, Seattle, WA, June 2018.
  • Hamel S, Sawinski D, Weinrieb R, Dave S, Trofe-Clark J. Outcomes in renal transplant recipients with bipolar disorder: a large retrospective cohort. Accepted as poster to the American Transplant Congress Meeting, Seattle, WA, June 2018.
  • Goswami Banerjee A, Hamel S, Weinrieb R, Dave S, Johnson V, Sawinski D, Trofe-Clark J. A retrospective matched case-control study of medical and psychiatric outcomes in renal transplant recipients with bipolar disorder. Accepted as poster to the Annual Meeting of the Academy of Consultation -Liaison Psychiatry, Orlando, FL, 2018.
  • Hamel S, Johnson V, Johnson D, Blumberg E, Bloom RD, Trofe-Clark J. Retrospective evaluation of dapsone prophylaxis complications in kidney transplant recipients. Accepted as poster to the American Transplant Congress Meeting, Boston, MA, June 2019.
  • Persun N, Johnson D, Leonberg-Yoo A, Bahrainwala J, Reese PP, Collins D, Houston M, Steiner B, Witmer B, Naji A, Trofe-Clark J. Two-year, single center, retrospective review of herbal supplement use in living kidney donors. Accepted as poster to the American Transplant Congress Meeting, Boston, MA, June 2019.
  • Goswami Banerjee A, Hamel S, Weinrieb R, Dave S, Johnson V, Sawinski D, Trofe-Clark J. A Retrospective matched case-control study of medical and psychiatric outcomes in kidney transplant recipients with bipolar disorder. Accepted as poster to the American Transplant Congress Meeting, Boston, MA, June 2019.
  • Trofe-Clark J, Brennan D, West-Thielke P, Milone MC, Lim MA, Bloom RD. Comparison of Pharmacokinetics and Pharmacogenomics of Once-daily Extended-release MeltDose® Tacrolimus Tablets (Envarsus® XR) vs. Twice-daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-over Study. Accepted as a Poster Presentation to the American Transplant Congress Meeting, Philadelphia, PA, May 2015.
  • Trofe-Clark J, Brennan D, West-Thielke P, Milone MC, Lim MA, Bloom RD. A Randomized Cross-Over Phase 3b Study of the Pharmacokinetics of Once-Daily Extended Release MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus in African-Americans (ASERTAA). Accepted as a Poster Presentation to the American Transplant Congress Meeting, Philadelphia, PA, May 2015. Awarded as a Poster of Distinction.
  • Reese PR, Bloom RD, Trofe-Clark J, Mussell A, Leidy D, Levsky S, Zhu J, Lin Y, Troxel A, Feldman H, Volpp K. Customized Reminders and Provider Notification to Improve Adherence to Immunosuppression. Accepted as a Poster Presentation to the American Transplant Congress Meeting, Philadelphia, PA, May 2015. Awarded as a Poster of Distinction.
  • Bloom RD, Brennan D, West-Thielke P, Milone MC, Trofe-Clark J. PK and Pharmacogenomics of Once-Daily-Meltdose® Tacrolimus (Envarsus® XR) vs Twice Daily Tacrolimus: A Randomized Cross-Over Study in Stable African American Kidney Transplant Patients (ASERTAA). Accepted as a Brief Oral presentation at the 17th Congress of the European Society for Organ Transplantation, Brussels, Belgium September 2015.
  • Koyawala N, Silber J, Rosenbaum P, Bloom R, Wang W, Hill A, Nazarian S, Sawinski D, Trofe-Clark J, Lim M, Schold J, Reese P. Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer. Accepted as a Poster to the American Transplant Congress Meeting, Boston, MA, June 2016.
  • Trofe-Clark J, Townsend R, Neubauer R, Lim MA, Callahan LA Bloom, RD. Pulse Wave Velocity amongst African-American Kidney Transplant Recipients Randomized to Once-daily MeltDose Tacrolimus Tablets (Envarsus XR) Vs. Traditional Twice-daily Tacrolimus Capsules: Exploratory Results from a Phase III Trial. Accepted as a Late Breaking Poster to the American Transplant Congress Meeting, Boston, MA, June 2016.
  • Trofe-Clark J, Gbemudu W, Truong J, Ryan S, Houston M, Shaffer J, Angerstein J, Barton N, Bleicher M, Goral S, Lim MA, Sawinski DA, Bloom RD, Reese PR. Pilot Study Results: Cognitive Function, Health Literacy, Transplant Related Medication Knowledge Base Assessments Early Post-Renal Transplant. Accepted as Oral Presentation to the 2017 Transplant Nursing Symposium, Lake Buena Vista, FL, June 2017.
  • Park J, Trofe-Clark J, Kaiser T, Pilch N, Taber D. Associations Between Provision of Transplant Pharmacy Services and Center-Level Patient and Graft Outcomes in U.S. Adult Kidney Transplant Programs. Accepted as Poster to the American Transplant Congress Meeting, Chicago, IL, May 2017.
  • Trofe-Clark J, Gbemudu W, Ryan S, Sawinski D, Lim M, Goral S, Bleicher M, Bloom RD, Reese PP. Assessments of Literacy, Cognitive Function and Transplant Medication Knowledge in Renal Transplant Recipients. Accepted as Poster to the American Transplant Congress Meeting, Chicago, IL, May 2017.
  • Goldberg DS, Blumberg EA, Reddy R, Nazarian SM, Van Deerlin V, Trofe-Clark J, Levine M, Sawinski D, Bloom R, Abt P, Reese P. Transplanting Hepatitis C Kidneys into Negative Kidney Recipients [THINKER] Trial. Accepted as Plenary Session to the American Transplant Congress Meeting, Chicago, IL, May 2017.
  • Kaur N, Kamoun M, Kearns J, Trofe-Clark J, Abt PL, Levine MH, Goral S. Kidney transplant outcomes in patients with CPRA values > 99% after implementation of the new OPTN/UNOS kidney allocation system (KAS): A single center study update. Accepted as poster to the American Transplant Congress Meeting, Seattle, WA, June 2018.
  • Cohen J, Lim MA, Tewksbury C, Torres Landa S, Trofe-Clark J, Abt PA, Williams N, Dumon K, Goral S. Bariatric surgery before and after kidney transplantation: long-term weight-loss and allograft outcomes. Accepted as poster to the American Transplant Congress Meeting, Seattle, WA, June 2018
  • Reece J, Steiner B, Bhoj V, Aqui N, Bloom RD, Trofe-Clark J. Large academic center experience with treatment of suspected/confirmed kidney transplant active antibody mediated rejection. Accepted as poster to the American Transplant Congress Meeting, Philadelphia, PA, May 2020.
  • Reece J, Steiner B, Bhoj V, Aqui N, Bloom RD, Trofe-Clark J. Banff criteria and the use of therapeutic plasma exchange in the treatment of suspected/confirmed kidney transplant active antibody mediated rejection: a large retrospective study. Accepted as an oral to the American Society for Apheresis, Austin, TX, May 2020.
Justin Harris, PharmD, BCPS, BCCP
Cardiology
  • Graveno M, Harris JR, Casciello N, Domenico C Sacubitril/valsartan Induced Vasoplegia Post-Ventricular Tachycardia Ablation 2019
  • Lenzi K, Capozzi D, Favatella J, Harris JR, Murphy M, Hecht T Pharmacist collaborative practice agreement implementation in an anticoagulation clinic 2019
  • Jean-Louis K, Fallah T, Harris JR, Evaluation of Therapeutic Enoxaparin Use Following Lung Transplantation 2018
  • Cenin D, Harris JR, Domenico C Evaluation of Permanent Pacemaker Insertion Antimicrobial Prophylaxis 2018
  • Lenzi K, Domenico C, Patel N, Harris JR, Time to therapeutic INR at the Hospital of the University of Pennsylvania 2018
  • Harris JR, Hatch R, Vallabhajosyula P, Patel N Morning Verse Evening Administration of Coumadin in Post-operative 2016-2019 Mechanical Valve Patients
Mitchell Hughes, PharmD, BCPS, BCOP
Ambulatory – Hematology/Oncology
  • Nasta SD, Namoglu EC, Hughes ME, Chong EA, Svoboda J, Ballard HJ, Landsburg DJ, LaRose MI, Barta SK, Gerson JN, Ruella M, Frey NV, Schuster SJ, Porter DL. Hospitalization patterns with commercial CAR T-cell therapy: A single institution experience. American Society of Hematology 61st Annual Meeting & Exposition. December 2019. Poster 3240.
  • Nasta SD, Hughes ME, Namoglu EC, Landsburg DJ, Chong EA, Barta SK, Frey NV, Gerson JN, Maity A, Plastaras J, Porter DL, Ruella M, Svoboda J, Ballard HJ, Schuster SJ. A characterization of bridging therapies leading up to commercial CAR T-cell therapy. American Society of Hematology 61st Annual Meeting & Exposition. December 2019. Poster 4108.
  • Svoboda J, Ballard HJ, Chong EA, LaRose MI, Bair SM, Namoglu EC, Hughes ME, Nasta SD, Landsburg DJ, Barta SK, Gerson JN, Weber E, Walling C, Ruella M, Frey NV, Porter DL, Schuster SJ. Use of bendamustine for lymphodepletion before tisagenlecleucel (anti-CD19 CAR T cells) for aggressive B-cell lymphomas. American Society of Hematology 61st Annual Meeting & Exposition. December 2019. Poster 1606.
  • Ho CI, Ballard HJ, Arscott WT, Hughes ME, Doucette A, Landsburg DJ, Nasta SD, Gerson JN, Maity A, Schuster SJ, Barta SK, Plastaras J, Svoboda J. Concurrent use of novel agents and radiation is tolerated in lymphoma patients. American Society of Hematology 61st Annual Meeting & Exposition. December 2019. Poster 2905.
  • Namoglu EC, Hughes ME, Landsburg DJ, Schuster SJ, Svoboda J, Chong EA, Gerson JN, Barta SK, Nasta SD. Clinical outcomes of non-Hodgkin lymphoma patients on acalabrutinib including off-label utilization. Blood. 2019;134 Supplement_1:5261.
  • Weiner DM, Robinson ND, Bair SM, Ballard HJ, Hughes ME, Nasta SD, Landsburg DJ, Barta SK, Chong EA, Schuster SJ, Svoboda. Outcomes and toxicities of ibrutinib in marginal zone lymphoma: A retrospective cohort study at a single institution. Blood. 2019;134 Supplement_1:5250.
  • Hughes ME, Namoglu EC, Suen C, Schuster SJ, Svoboda J, Landsburg DJ, Barta SK, Gerson JN, Robinson K, Chong EA, Rhodes JM, Ayers EC, Loren AW, Stadtmauer EA, Nasta SD. Clinical outcomes of obinutuzumab therapy across non-Hodgkin lymphoma subtypes. Blood. 2019;134 Supplement_1:5247.
  • Ciervo J, Owens A, Capozzi D, Hughes ME. Assessment of patients understanding and anxiety related to cancer treatment after implementation of an interdisciplinary team education program. American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition Vizient Presentation. December 2019.
  • Cenin CA, Timlin C, Hughes MEH, Freyer CW, Radcliff JA, Plastaras JP, McCurdy SR. Characterizing the incidence of pneumonitis in allogeneic hematopoietic stem cell transplant receiving total body irradiation. American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition Vizient Presentation. December 2019.
  • Hughes, ME, Barta S, Capozzi DL, Chong E, Chong E, Gerson J, Landsburg DJ, Latorre T, Nasta S, Robinson K, Svoboda J, Timlin C, Walsh K, Schuster SJ. MeRIT Project: A pharmacogenomics evaluation of ibrutinib for treatment of B-cell malignancies. American College of Clinical Pharmacy Annual Meeting. October 2019. MeRIT Poster 06.
  • Suen CT, Hughes ME, Timlin C, Cambareri C, Kriska R, Strong G, Favatella JK, Demers R, Capozzi DL. Appropriate prescribing of antiemetics with oral oncolytic therapy: A single center experience. Journal of Drug Assessment. 2019;8:12.
  • Hughes ME, Kriska R, Strong G, Chung J, Nguyen L, Rubin DJ, Murphy M, Favatella JK, Capozzi DL. Implementation of an internal check of oral oncolytics: A single-center, specialty pharmacy safety initiative. Journal of Drug Assessment. 2019;8:25.
  • Hughes ME, Suen C, Namoglu E, Schuster SJ, Svoboda J, Loren A, Nasta SD. Obinutuzumab therapy in patients with marginal zone and mantle cell lymphoma. International Conference on Malignant Lymphoma. June 2019. Abstract 362.4.
  • Hughes ME, Suen C, Namoglu E, Schuster SJ, Svoboda J, Landsburg DJ, Rhodes J, Loren A, Stadtmauer E, Nasta SD. Real world outcomes of obinutuzumab monotherapy in patients with chronic lymphocytic leukemia. International Conference on Malignant Lymphoma. June 2019. Abstract 334.
  • Suen C, Cenin DA, Hughes ME, Timlin C, Freyer CW, Landsburg DJ. Evaluation of the incidence and clinical characteristics of invasive fungal and opportunistic infections in patients receiving ibrutinib for lymphoid malignancies. Poster presentation for the Hematology/Oncology Pharmacy Association’s 15th Annual Conference. April 2019. Poster TR091.
  • Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks K, Gao L, Winter AM, Hill BT, Ondrejka S, Hsi E, Nasta SD, Svoboda J, Schuster SJ, Bogusz AM. Outcome of patients with relapsed/refractory double expressor B cell lymphoma treated with ibrutinib monotherapy. American Society of Hematology 60th Annual Meeting & Exposition. December 2018. Oral Abstract 0455.
  • Freyer CW, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy S, Perl AE, Porter DL, Luger S. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation: A single center characterization of risk factors and an assessment of supplementation practice. American Society of Hematology 60th Annual Meeting & Exposition. December 2018. Abstract 4023.
  • Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Tsai DE, Robinson K, Gill SI, Mato AR, Gerson JN, Land D, Shelly B, McLeish A, Rago A, Gill J, Walsh K, Latorre T, Altman S, Timlin C, Capozzi D, Nasta SD. Venetoclax therapy in patients with relapsed/refractory (ras (NHL). American Society of Hematology 60th Annual Meeting & Exposition. Poster Presentation December 2018. Abstract 1706./r) Non Hodgkin Lymphom
  • Hughes ME, Jensen C, Svoboda J, Strelec LE, Youngman MR, Schuster SJ, Landsburg DJ, Nasta SD, Tsai DE, Mintzer DM, Gill J, Dorsey C, Kennard K, Chatburn ET, Rhodes J, Isaac K, Walsh K, Latorre T, Piersanti K, Bannister E, Timlin C, Capozzi D, Mato AR. Clinical outcomes of anti PD-1 immunotherapy in patients with relapsed/refractory non Hodgkin lymphomas. American Society of Hematology 59th Annual Meeting & Exposition. December 2017. Abstract 1575.
  • Song Y, Schuster SJ, He W, Zhu J, Deng L, Sun Y, Ding N, Wang X, Gill J, Chatburn ET, Kennard K, Anderson BD, Nasta SD, Landsburg DJ, Porter DL, Napier E, Hughes ME, Latorre T, Walsh K, Dorsey C, Svoboda J, Addis V, Mato AR. Simultaneous global phase I studies of a differentiated BTK inhibitor, Dtrmwxhs-12, in relapsed/refractory patients with chronic lymphocytic leukemia and B-cell lymphomas. American Society of Hematology 59th Annual Meeting & Exposition. December 2017. Abstract 4056.
  • Mato AR, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Beach DF, Pu JJ, Sehgal AR, Winter AM, Zent CS, Tuncer HH, Singavi AK, Schuster SJ, Pickens PV, Shah NN, Williams A, Howlett C, Weissbrot H, Ali N, Patel B, Isaac K, Rhodes J, Hughes ME, Khajavian S, Chatburn ET, Sitlinger A, Tranchito E, Bhavsar EB, Bailey N, Burns TF, Yacur M, Malhotra M, Handunnetti S, Kennard K, Nabhan C, Ujani CS. Front-line ibrutinib therapy for chronic lymphocytic leukemia (CLL) in the real world: Responses, toxicity, outcomes and subsequent therapies. American Society of Hematology 59th Annual Meeting & Exposition. December 2017. Abstract 3011.
  • Mato AR, Dorsey C, Chatburn ET, Geoghegan J, Schuster SJ, Svoboda J, Becker PS, Chong EA, Nasta SD, Landsburg DJ, Kennard K, Luning-Prak E, Tsao P, Hughes ME, Purdom M, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Shadman M. Phase I/II study of pembrolizumab in combination with ublituximab (TG-1101) and umbralisib (TGR-1202) in patients with relapsed/refractory CLL. American Society of Hematology 59th Annual Meeting & Exposition. December 2017. Abstract 3010.
  • Isaac K, Kennard K, Landsburg DJ, Hughes ME, Svoboda J, Nasta S, Latorre T, Surkis W, Fanning MJ, Chatburn E, Dorsey C, Daniel C, Timlin C, Gill J, Schuster SJ, Mato AR. Clinical outcomes of DLBCL, follicular lymphoma (FL) and Richter transformation (RT) patients treated with ibrutinib: A real-world experience of off-label ibrutinib use. J Clin Oncol. 2017;35(15):suppl,e19043-e19043.
  • Gashonia LM, Carver JR, O’Quinn R, Clasen S, Hughes ME, Schuster SJ, Isaac K, Kennard K, Svoboda J, Daniel C, Tsai DE, Fanning MJ, Nasta S, Landsburg DJ, Nabhan C, Mato AR. Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience. ASCO Annual Meeting; Abstract 7525. June 2017.
  • Mato AR, O’Quinn, Bange E, Gashonia L, Clasen S, Svoboda S, Nasta S, Landsburg DJ, Strelec L, Nabhan C, Pickens P, Ali N, Kennard K, Dorsey C, Hughes ME, Tsai DE, Isaac K, Rhodes J, Porter D, Schuster S, Carver J. Left atrial abnormality as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. International Workshop on Chronic Lymphocytic Leukemia. Oral Abstract. May 2017.
  • Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner E, Loren AW, Luger SL, Mangan JK, Smith J, Stadtmauer EA, Freyer CW, Gilmar C, Porter DL. Oral vancomycin is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic stem cell transplant recipients. ASH 58th Annual Meeting & Exposition; Abstract 2225. December 2016.
  • Hughes ME, Patel N, Domenico C, Krause TM, Timlin C, Ganetsky A. Association between tacrolimus concentrations and hypertension in allogeneic hematopoietic stem cell transplant recipients. Poster presentation for the Hematology/Oncology Pharmacy Association’s 12th Annual Conference. March 2016. Poster CR15.
  • Hughes ME, Favatella J, Vozniak M, Gibson G. Impact of a unit based clinical pharmacy practice model in a large, academic medical center oncology unit. Poster presentation for the Hematology/Oncology Pharmacy Association's 12th Annual Conference. March 2016. Poster
Share This Page: